Exhibit 10.1


 





Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked
“***” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment
Request with the Commission.


 





OMB Approval 2700-0042


	 	1.
    CONTRACT ID CODE	PAGE
        OF    PAGES
	AMENDMENT
    OF SOLICITATION/MODIFICATION OF CONTRACT	 	1	3
	2.  AMENDMENT/MODIFICATION
    NO.	3.  EFFECTIVE DATE	4.  REQUISITION/PURCHASE
    REQ. NO.	5.  PROJECT NO. (If applicable)
	Nineteen
    (19)	August 10, 2016	4291173:	 
	6.  ISSUED BY	CODE	 	7. ADMINISTERED BY (If other than Item 6)

         
	CODE	N/A
	National Institutes of Health

        National Institute of Allergy and Infectious
        Diseases

        DEA, Office of Acquisitions

        Room 3214, MSC 7612

        6700-B Rockledge Drive

        Bethesda, MD 20892-7612

         
	 

        MID RCB-A

	8.  NAME AND ADDRESS OF CONTRACTOR (No.
    Street, county, State and ZIP: Code)	(X)	9A. AMENDMENT OF SOLICITATION NO.
	.

         

         
	 	 
	BIOCRYST PHARMACEUTICALS, INC.
	 	9B.  DATED (SEE ITEM 11)
	4505 EMPEROR BLVD SUITE 200
	 	 
	DURHAM, NC 27703	 	10A.  MODIFICATION OF CONTRACT/ORDER NO.
	 	X	  HHSN272201300017C
	 	 	10B.  DATED (SEE ITEM 13)
	CODE	FACILITY
    CODE	 	September 16, 2013
	11.  THIS
    ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
	[_] The above numbered
                     solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers [_] is extended,
                     [_] is not extended.

         

        Offers must acknowledge receipt
        of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:

         

        (a) By completing Items 8
        and 15, and returning one (1) copy of the amendment; (b) By acknowledging receipt of this amendment on each copy of the
        offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers.
        FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND
        DATA SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already
        submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation
        and this amendment, and is received prior to the opening hour and data specified.

         

	12.  ACCOUNTING
    AND APPROPRIATION DATA (If required)
	SOC 25.55  16-8019776   $2,672,620
    16-8470038 $1,454,077 Total $4,126,697
	13. THIS ITEM APPLIES ONLY
        TO MODIFICATIONS OF CONTRACTS/ORDERS,

        IT MODIFIES THE CONTRACT/ORDER
        NO. AS DESCRIBED IN ITEM 14.

	 	A. THIS CHANGE ORDER
    IS ISSUED PURSUANT TO:  (Specify authority)   THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN
    THE CONTRACT ORDER NO. IN ITEM 10A.
	 	 
	 	B. THE ABOVE NUMBERED
    CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date,
    etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).
	 	C. THIS
                                                                                         SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

         

         

	X	D.
OTHER Specify type of modification and authority)

        Mutual Agreement of the Parties.

	E.  IMPORTANT:  Contractor
    [_] is     not, [X] is required to sign this document and return      copies
    to the issuing     office.
	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized
        by UCF section headings, including solicitation/contract subject matter where feasible.)

         

        PURPOSE:
Execute Option 10

         

         

        The completion date of the
        contract is changed to December 30, 2017.

        Total cost obligated by this
        action is changed $4,126,697

        Total contract ceiling is
$39,476,895

         

	Except as provided herein,
    all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full
    force and effect.
	15A.  NAME AND
    TITLE OF SIGNER   (Type or print)	16A.  NAME AND TITLE OF CONTRACTING OFFICER   (Type
    or print)
	Jon P. Stonehouse

    CEO	John Outen, Contracting Officer

        Office of Acquisitions, DEA, NIAID, NIH,
        DHHS

	15B.  CONTRACTOR/OFFEROR	15C.  DATE
    SIGNED	16B. UNITED STATES
        OF AMERICA
	16C.  DATE SIGNED
	/s/ Jon P. Stonehouse

        (Signature of person authorized
        to sign)
	 	BY /s/ John
        Outen

        (Signature of Contracting
        Officer)
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 





	NSN 7540-01-152-8070

                           PREVIOUS EDITION UNUSABLE
	30-105

                                               Computer
                                         Generated
	STANDARD FORM 30 (REV. 10-83)

                           Prescribed by GSA

                           FAR (48 CFR) 53.243










 



     

     

    




	
        SPECIAL PROVISIONS

         

         
	
        Contract No. HHSN272201300017C

        Modification No.19

         
	   Page 2 of 3


 


Beginning with the effective date of this modification, ARTICLE
B.2. ESTIMATED COST –OPTION AND ARTICLE G.3 INVOICE SUBMISSION /CONTRACT FINANCING REQUEST IS REVISED


 


ARTICLE B.2. ESTIMATED COST – OPTION is revised to incorporate changes for
execution of Option 10 with changes in the Option table below:


		a.	The
estimated cost ceiling of this contract is $39,476,895 with the execution of this option. The obligation for this action is $4,126,697



 





		c.	Payments
from the base and executed options will be made from the following PRISM/NBS Line Item Numbers as follows:



 


	PRISM/NBS
    Line Item No.	Option/Increment
    Description	PRISM/NBS
    Line Item

    Period of Performance	Funded
    Amount	 
	 

        1

        (BASE)

        Award
	Base
    Period:  Non-GMP manufacture of drug substance, drug disposition, genetic toxicity and in vitro and small animal efficacy
    studies	 

        09/16/2013- 03/31/2015
	 

        $ ***
	 
	2

        (Option 1)

        Award
	Option 1-Manufacture of drug substance

        and drug product in compliance with cGMP guidance
        -GMP
	 

        09/16/2013 -12/30/2017
	 

        $ ***
	 
	3

        (Option 2)

        Award
	Option
    2-DP and Development with DS Stability testing	 

        09/16/2013 -12/30/2017
	 

        $ ***
	 
	4

        (Option 3)

        MOD 1
	Option 3-IM IND-Enablement

        and Submission
	 

        12/24/2013 -12/23/2016
	 

        $2,506,042
	 
	5

        (Option 4)

        MOD 5
	Option
    4- IM Phase 1 Clinical Trials	 

        08/08/2014-06/30/2017
	 

        $ ***
	 
	6
    (MOD 6)	Line
    is Cancelled	Line
    is cancelled	$0	 
	7

        (Option 6)

        Mod 3
	Option 6-IV DP Development and Non-GMP Activities

         
	 

        5/25/2014 - 09/30/16
	 

        $1,886,304
	 
	8

        (Option 7)

        Mod 8
	 

        Option 7- IV GMP DS for Phase 1

        Manufacturing
	 

        9/17/2014 - 12/30/2017
	 

        $ ***
	 
	9

        (Option 8)

        Mod 8
	 

        Option 8 – IV DP Stability for eGMP/ICH Manufacturing
	 

        9/17/2014 - 12/30/2017
	 

        $ ***
	 
	10

        (Option 9)
	Option
    9 - IV IND-Enablement and Submission	 

        12/10/2014 -09/04/2017
	 

        $2,718,329
	
         

         

	11

        (Option 10)

        Modification 19
	 

        Phase 1 IV Clinical Trials

         
	 

        8/10/2017-12/30/2017
	 

        $4,126,697
	 
	12

        (Option 5)

        MOD 7&8
	Option 5- Characterization of Efficacy in a Therapeutic
        NHP infection model

        (Equitable Adjustment)
	 

        8/08/2014 - 12/30/2017
	 

        $ ***
	 



 





Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked
“***” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment
Request with the Commission.



     

     

    







	
        SPECIAL PROVISIONS

         

         
	 	   Page 3 of 3




 


 





	13

        (Option 5)

        Mod 7&8
	Option 5- Characterization of Efficacy in a Therapeutic
        NHP infection model

        (Cost Overrun)
	 

        8/08/2014 - 12/30/2017
	 

        $ ***
	
         

         

         

	14

        (Option 1)

        Mod 12
	Option 1-Manufacture of drug substance

        and drug product in compliance with cGMP guidance
        –GMP-Added Kg
	 

        09/16/2013 -12/30/2017
	 

        $ ***
	 
	15

        (Option 2)

        Mod 12
	Option
    2-DP and Development with DS Stability testing-Added testing	 

        09/16/2013 -12/30/2017
	 

        $ ***

         
	
         

         

	16

        (Option 5) Mod 7&8
	Option
    5- Characterization of Efficacy in a Therapeutic NHP infection model (Cost Overrun)	 

        8/08/2014 - 12/30/2017
	 

        $ ***
	 
	17

        (Option 4) Cost Overrun
	Option
    4- IM Phase 1 Clinical Trial	 

        08/08/2014- 06/30/2017
	 

        $1,344,780
	
         

         

	18

        (Option 5) Equitable Adjustment
	Option
    5- Characterization of Efficacy in a Therapeutic NHP infection model.	 

        9/15/2015 - 12/30/2017
	 

        $2,184,734
	
         

         

         

	19

        (Option 5) Equitable Adjustment
	Option
    5- Characterization of Efficacy in a Therapeutic NHP infection model. Additional primate studies	 

        6/30/2016 - 12/30/2017
	 

        $5,475,146
	 


 


 


 


 


END OF MODIFICATION 19 OF HHSN272201300017C


 





 


 


 


 


 


 


Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked
“***” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment
Request with the Commission.